Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION KSLION to Stimulate Innovation in Life Science in Japan: Prof. Y. Natsumeda
March 5, 2012
-
BUSINESS Medipal Group to Determine Profitability with Each Customer: Next President Shuichi Watanabe
March 2, 2012
-
BUSINESS DSP to Acquire Boston Biomedical, US Bioventure Specializing in Oncology
March 1, 2012
-
BUSINESS Pfizer Japan to Set Up Rare Disease Division
February 29, 2012
-
REGULATORY MHLW Conducts Hearing on Distribution Improvement with Drug Manufacturers
February 28, 2012
-
REGULATORY Next 5-Year Strategy Calls for Boost to Japanese“Rising Sun”Seed Development
February 27, 2012
-
REGULATORY PAFSC’s First Committee on Drugs Recommends Approval for Eli Lilly’s Once-Weekly GLP-1 Receptor Agonist
February 27, 2012
-
BUSINESS Diabetes Treatments: Their Development and Market (2)
February 27, 2012
-
BUSINESS Daiichi Sankyo and Terumo Codevelop Intradermal Vaccine
February 24, 2012
-
REGULATORY MEXT to Make Drug Education Compulsory at Junior High Schools from FY2012
February 23, 2012
-
BUSINESS Novo Nordisk President Says “Current Pipeline Most Substantial”
February 22, 2012
-
ORGANIZATION Japan Pharmaceutical Political Association Chairman Kumakura to Focus on Resolving Price Difference
February 21, 2012
-
REGULATORY MHLW Issues Improvement Order to Janssen Pharmaceutical for GMP Violation
February 20, 2012
-
BUSINESS Diabetes Treatments: Their Development and Market
February 20, 2012
-
BUSINESS 6 SGLT-2 Inhibitors in Final Development Stage, Applications Expected in 2013
February 17, 2012
-
BUSINESS Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic Ahead of Competitors
February 16, 2012
-
REGULATORY Over 30 Companies Target Nu-lotan Generic Listing in June, 60% Pricing Rule to Apply
February 15, 2012
-
BUSINESS Dispensing Pharmacies Set to Reopen in Disaster-Hit Areas
February 14, 2012
-
REGULATORY Healthcare Providers, Bill Payers in Face-Off Over Additional Premiums for Generic Name Prescriptions
February 13, 2012
-
BUSINESS Nichi-Iko to Shift Back Priority to Its Own Generics from Transferred Long-Listed Products
February 13, 2012
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…